Comparison of efficacy and safety of nab-paclitaxel and oxaliplatin + S-1 and standard S-1 and oxaliplatin chemotherapy regimens for treatment of gastric cancer

Table 1 Basic patient characteristics and short-term efficacy, n (%)

Variables	Total (n = 219)	P-SOX (n = 149)	SOX (n = 70)	Z	P value
Age				2.674	0.102
≤ 60	142 (64.8)	102 (68.5)	40 (57.1)
> 60	77 (35.2)	47 (31.5)	30 (42.9)
Sex				0.514	0.473
Male	184 (84)	127 (85.2)	57 (81.4)
Female	35 (16)	22 (14.8)	13 (18.6)
BMI				0.278	0.598
18.5–24	140 (63.9)	97 (65.1)	43 (61.4)
< 18.5 or > 24	79 (36.1)	52 (34.9)	27 (38.6)
ASA				0.168	0.681
1+2	178 (81.3)	120 (80.5)	58 (82.9)
3	41 (18.7)	29 (19.5)	12 (17.1)
RECIST 1.1				1.906	0.167
Ineffective	104 (47.5)	66 (44.3)	38 (54.3)
Effective	115 (52.5)	83 (55.7)	32 (45.7)
TRG				1.324	0.250
Effective	128 (58.4)	91 (61.1)	37 (52.9)
Ineffective	91 (41.6)	58 (38.9)	33 (47.1)
Tumor location				0.260	0.878
Lower	76 (34.7)	51 (34.2)	25 (35.7)
Upper	69 (31.5)	46 (30.9)	23 (32.9)
Middle	74 (33.8)	52 (34.9)	22 (31.4)
Differentiation				1.883	0.390
Poorly	101 (46.1)	64 (43)	37 (52.9)
Moderate	72 (32.9)	52 (34.9)	20 (28.6)
Well	46 (21)	33 (22.1)	13 (18.6)
cT stage				0.384	0.825
2	60 (27.4)	42 (28.2)	18 (25.7)
3	117 (53.4)	80 (53.7)	37 (52.9)
4	42 (19.2)	27 (18.1)	15 (21.4)
cN stage				0.155	0.694
Negative	76 (34.7)	53 (35.6)	23 (32.9)
Positive	143 (65.3)	96 (64.4)	47 (67.1)
cTNM1				1.170	0.557
II	120 (54.8)	83 (55.7)	37 (52.9)
III	52 (23.7)	37 (24.8)	15 (21.4)
IV	47 (21.5)	29 (19.5)	18 (25.7)
Tumor diameter				2.196	0.333
≤ 2	55 (25.1)	33 (22.1)	22 (31.4)
2-5	91 (41.6)	64 (43)	27 (38.6)
≥ 5	73 (33.3)	52 (34.9)	21 (30)
Laurnen				3.274	0.195
Enteric	42 (19.2)	29 (19.5)	13 (18.6)
Mixed type	98 (44.7)	72 (48.3)	26 (37.1)
Diffuse	79 (36.1)	48 (32.2)	31 (44.3)

¹Tumor location is classified as upper 1/3, middle 1/3, lower 1/3, diffuse TNM staging according to the American Cancer Consortium.

ASA: American Society of Anesthesiologists Score; BMI, body mass index; RECIST: Response Evaluation Criteria in Solid Tumors; TRG: Tumor Regression Grade; P-SOX: Nab-paclitaxel and oxaliplatin + S-1; SOX: Standard S-1 and oxaliplatin.